Davis R J, Agnew D K, Shealy C R, Friedman S E
Department of Orthopaedic Surgery, University of South Carolina School of Medicine, Columbia.
J Pediatr Orthop. 1993 Nov-Dec;13(6):781-3. doi: 10.1097/01241398-199311000-00019.
Awareness of the potential for transmission of the spread of viral diseases through homologous blood products has led to an increasing awareness of techniques that minimize these risks. Reinfusion of postoperatively shed blood has become popular, but its efficacy has been questioned. In an effort to determine the viability of postoperatively collected cells, 10 consecutive patients undergoing an identical surgical procedure were studied; their blood was tagged with chromium 51 and reinfused. Reinfused cells were then monitored serially at determined intervals and expressed as a percentage of postinfusion activity. At 4 days, 75.9% of initial activity remained. These figures are comparable to those previously reported for intraoperative and preoperative cell collection. Blood salvaged postoperatively is not significantly damaged and is as viable as blood collected from other autologous and homologous sources.
意识到通过同源血液制品传播病毒性疾病的可能性,人们越来越关注将这些风险降至最低的技术。术后回输流失的血液已变得很普遍,但其疗效受到质疑。为了确定术后采集细胞的活力,对10例接受相同外科手术的连续患者进行了研究;他们的血液用铬51标记后回输。然后在确定的间隔时间对回输的细胞进行连续监测,并表示为输注后活性的百分比。在第4天,初始活性的75.9%仍然存在。这些数字与先前报道的术中及术前细胞采集的数字相当。术后回收的血液没有受到明显损害,其活力与从其他自体和同源来源采集的血液一样。